Acne Drugs Market:
WiseGuyReports.com adds “Acne Drugs Global Market Report 2022” reports to its database.
Acne is considered a common dermatological condition, which affects a major chunk of population worldwide. Abnormal production of hormone is a major causative factor. Increased levels of androgen during puberty trigger the onset of acne by enlarging the oil glands present under the skin. This further result in excess production of sebum, which breaks down cell walls in pores and results in bacterial invasion. Factors such as, genetic causes, emotional stress, climate change, menstruation, and greasy cosmetics are estimated to trigger the growth of acne in an individual.
With sedentary and unhealthy lifestyle, increasing disposable income of the global population, and surging prevalence of the upcoming trends in acne, the global acne drugs market is estimated to gain major growth in the coming few years.
Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4588872-acne-drugs-global-market-report-2020-including-1
The global acne drugs market was valued at about $15.45 billion in 2018 and is expected to grow to $20.48 billion at a CAGR of 7.3% through 2022.
Major players in the market are ALLERGAN, Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd. and Johnson & Johnson Services, Inc.
The global acne drugs market has been segmented on the basis of type, therapeutic class, and end-user.
By type, the global acne drugs market is segmented into inflammatory acne and non-inflammatory acne. Of these, the inflammatory acne is likely to command the largest share globally. This type generally occurs when pores are clogged deeply, which results in redness and swelling.
The end-user segment of acne drugs market comprises pharmacies & drug stores, hospitals & clinics, and ambulatory surgical centres. Of these, hospitals and clinics are likely to gain prominence due to the availability of advanced treatment procedures and favorable reimbursement policies.
Based on the therapeutic class, the market is segmented into antibiotics, retinoids, benzoyl peroxide, and salicylic acid. Of these, retinoids and antibiotics segment are likely to remain the mainstay of acne drugs market.
Considering the global scenario, the acne drugs market spans across Western Europe, Asia Pacific, North America, Eastern Europe, the Middle East, Africa, and South America.
Considering the global scenario, North America commands the largest market share in the acne drugs market. The region is anticipated to retain its pole position in the coming years due to the rising incidences of acne among the global population. In this region, the U.S. is predicted to garner major share due to the presence of better acne treatment options, greater awareness associated with acne treatments, and growing affordability of the people in the region.
The Asia Pacific, on the other hand, is estimated to expand at a robust rate, mainly due to an increased sedentary lifestyle, coupled with unhealthy food habits among the global population. A faster pace of life has also changed eating habits of the people here. Consumption of high amount of calories and fats and less exercise have resulted in problems associated with acne and obesity. Affordability in treatment options, increasing awareness regarding medication and safe acne products, and growing healthcare expenditure are some of the chief factors likely to augment the market growth over the forecast period.
October 2019: A specialty manufacturing company, Foamix Pharmaceuticals Ltd. has recently declared that the U.S. FDA has approved AMZEEQTM topical foam, which was previously known as FMX101. The novel drug is meant for the treatment of inflammatory lesions and non-nodular moderate, which serves acne vulgaris in adults as well as in paediatric patients.
For further information on this report, visit – https://www.wiseguyreports.com/reports/4588872-acne-drugs-global-market-report-2020-including-1
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)